What to do as a gynecologic oncologist during the COVID-19 pandemic? MEMAGO statement

dc.contributor.authorAtallah, David M.
dc.contributor.authorAbdel Khalek, Yara
dc.contributor.authorMutlu Meydanlı, Mehmet
dc.contributor.authorEl Kassis, Nadine
dc.contributor.authorAbdallah, Reem M.
dc.contributor.authorAyhan, Ali
dc.contributor.authorKhoury, Clement
dc.contributor.authorChahine, Georges Y.
dc.contributor.authorTaşkiran, Çaǧatay
dc.contributor.authorKöse, Mehmet Faruk
dc.contributor.authorSeoud, Muhieddine A.F.
dc.contributor.departmentObstetrics and Gynecology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:05Z
dc.date.available2025-01-24T12:08:05Z
dc.date.issued2020
dc.description.abstractThe SARS-Cov-2 virus pandemic causes an acute public health emergency with millions of infected patients and thousands of deaths. The infection makes adults prone to severe and fatal consequences, especially when they suffer several comorbidities. Our oncologic patients are the most susceptible to its severe repercussions because of their initial diagnosis and the immunosuppressive adjuvant and neoadjuvant treatments they receive. The Chinese CDC reported a 5.6% risk of mortality among cancer patients compared to 0.9% in the general population; likewise, other studies showed a twofold higher risk of death in this patients’ subgroup. In order to maintain the best quality of medical services during this crisis, along with the safety of healthcare providers, accurate triage of our oncologic patients must be done before any medical or surgical intervention to decide whether or not postponing treatments may be considered, without risking the disease progression and patients’ worsening outcomes, otherwise inpatient and outpatient special precautions must be followed whenever interventions are currently scheduled, according to each gynecologic cancer type. The disease is worldwide but local and regional circumstances vary, thus practice guidelines must be individualized according to each country virus prevalence and available medical resources, in order to limit the burden of the COVID-19 infection on the health system during the crisis and the upcoming months after its resolution. © 2020 Lebanese Order of Physicians. All rights reserved.
dc.identifier.eid2-s2.0-85094607446
dc.identifier.urihttp://hdl.handle.net/10938/31707
dc.language.isoen
dc.publisherLebanese Order of Physicians
dc.relation.ispartofJournal Medical Libanais
dc.sourceScopus
dc.subjectCovid
dc.subjectGynecologic oncology management
dc.subjectAntineoplastic agent
dc.subjectAdjuvant therapy
dc.subjectAdvanced cancer
dc.subjectArticle
dc.subjectCancer patient
dc.subjectCancer surgery
dc.subjectCoronavirus disease 2019
dc.subjectDisease exacerbation
dc.subjectEarly cancer
dc.subjectEmergency health service
dc.subjectEndometrium cancer
dc.subjectFemale genital tract cancer
dc.subjectFollow up
dc.subjectGynecologic oncologist
dc.subjectHealth care personnel
dc.subjectHealth care system
dc.subjectHigh risk patient
dc.subjectHospital patient
dc.subjectHuman
dc.subjectInformed consent
dc.subjectMortality risk
dc.subjectNeoadjuvant chemotherapy
dc.subjectOutcome assessment
dc.subjectOutpatient care
dc.subjectOvary cancer
dc.subjectPandemic
dc.subjectPhysician attitude
dc.subjectPostoperative care
dc.subjectPractice guideline
dc.subjectPreoperative care
dc.subjectPsychological aspect
dc.subjectTherapy delay
dc.subjectUterine cervix cancer
dc.subjectUterine cervix tumor
dc.subjectVulva cancer
dc.titleWhat to do as a gynecologic oncologist during the COVID-19 pandemic? MEMAGO statement
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-3516.pdf
Size:
2.64 MB
Format:
Adobe Portable Document Format